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taking oral contraceptives (OC) represent the most classical cir-
cumstance of HCA appearance. In recent years, clinical diagnosis
of focal nodular hyperplasia (FNH) vs HCA has signiﬁcantly
improved due to the wide use of contrast agent ultrasonography
and magnetic resonance imaging (MRI). However, there are cir-
cumstances where the differential diagnosis remains difﬁcult
and consequently require specimen resection. In addition, the
diagnosis of benign hepatocellular nodules has greatly beneﬁted
from the contribution of molecular biology [1–3] allowing for the
differential diagnosis between FNH and HCA and the identiﬁca-
tion of HCA subtypes. To date three major subtypes have been
identiﬁed: HNF1A mutated HCA (H-HCA), b-catenin mutated
HCA (b-HCA), and inﬂammatory HCA (IHCA). IHCA can be also
b-catenin mutated (b-IHCA). Less than 10% of HCA remain unclas-
siﬁed. A phenotypic classiﬁcation of those benign tumors using
immunohistochemistry has been derived from the above-men-
tioned molecular characterization. Liver fatty acid binding pro-
tein (LFABP), serum amyloid A (SAA)/C reactive protein (CRP),
glutamine synthase (GS), and b-catenin immunohistochemical
analyses performed on surgical specimens discriminate FNH from
HCA and identify the different HCA subtypes (Table 1) [4–8]. The
advantages of immunohistochemistry-based approaches are (i)
simplicity (can be performed on formalin ﬁxed, parafﬁn-embed-
ded tissue), (ii) reproducibility and (iii) easiness to analyze (in
most cases). Brieﬂy, the use of molecular markers and its patho-
logical counterparts has allowed (i) to clearly separate FNH from
HCA by introducing the previously called telangiectatic FNH [9]
in the subgroup of IHCA, (ii) to identify different clinical, biolog-
ical, radiological, and pathological HCA subtypes andmost impor-
tantly (iii) to identify HCA at risk to malignant transformationJournal of Hepatology 20
qDOI of original article: 10.1016/j.jhep.2010.10.030.
⇑ Corresponding author at: Pathology Department, Pellegrin Hospital, 33076
Bordeaux, France. Tel: +33 5 56 79 56 02; fax: +33 5 56 79 60 88.
E-mail address: paulette.bioulac-sage@chu-bordeaux.fr (P. Bioulac-Sage).
Abbreviations: HCA, hepatocellular adenoma; OC, oral contraceptives; FNH, focal
nodular hyperplasia; MRI, magnetic resonance imaging; H-HCA, HNF1A mutated
HCA; b-HCA, b-catenin mutated HCA; IHCA, inﬂammatory HCA; LFABP, liver fatty
acid binding protein; SAA, serum amyloid A; CRP, C reactive protein; GS, gluta-
mine synthase; HCC, hepatocellular carcinoma.into hepatocellular carcinoma (HCC) [10]. One of the most inter-
esting discoveries resulting from these analyses was the highest
percentage of overweight patients with IHCA (b-catenin mutated
or not) compared to other subtypes and the presence of an
inﬂammatory syndrome in IHCA [11].
In this issue [12] Van Aalten and co-workers report their expe-
rience using the HCA classiﬁcation described above [4]. They con-
ﬁrm that immunohistochemistry markers are useful in typing
HCA in more than 90% of cases tested and that this classiﬁcation,
including the identiﬁcation of b-catenin positive HCA may have
important implications in the decision process for surveillance
or treatment. They analyze 71 lesions of which 14 were identiﬁed
as FNH and 57 as HCA. Van Aalten and colleagues also conﬁrm
that the map-like pattern of GS staining was very useful to char-
acterize FNH. The population studied in terms of age, gender,
clinical manifestations including bleeding, number, and size of
nodules was unremarkable. Of note, none of the speciﬁc HCA eti-
ology (i.e. glycogenosis) was present. Among the HCA identiﬁed
in this study, 19% (11 cases) were LFABP negative, 63% (36 cases)
were IHCA expressing SAA and CRP (4 expressing GS and 3 out 4
aberrant b-catenin), 7% (4 cases) were b-catenin positive, and 11%
(6 cases) remained unclassiﬁed. The numbers reported are of the
same magnitude than those obtained in France on a large popu-
lation using molecular and/or immunohistochemistry [11]. The
sample series analyzed in the Van Aalten study was, however,
too small to draw any valid conclusion concerning the inﬂuence
of subtype on hemorrhagic risk, size, body mass index, follow-
up for unresected HCA, malignant transformation even in b-
catenin mutated HCA. Of interest in their paper was the presence
of two different subtypes in the same patient. Unclassiﬁed HCA
were associated with a b-catenin mutated HCA in one case and
with IHCA in another case. These data could suggest, as the
authors mentioned, that unclassiﬁed HCA may be acquired with
time with another phenotype, but this needs to be conﬁrmed in
a larger series and with molecular tools.
Will the pathomolecular classiﬁcation of HCA improve their
management? (Fig. 1) Will it change our policy based on size
[11,13]? At the present time, the policy is to resect tumors
P5 cm to avoid complications (hemorrhage and HCC). To be able
to answer this question, it is necessary to classify the tumors11 vol. 55 j 8–10
Table 1. HCA subtypes: pathological and immunohistochemical features for diagnosis.
HCA diffuse steatosis rosette formation  
some cytological atypia 
inflammatory infiltrate
sinusoidal dilatation
thick arteries
ductular reaction
idem IHCA + β-cat no specificity
NT frequent steatosis
(obesity)
frequent steatosis
(obesity)
HCA - + + + +
NT + + + + +
HCA - - + + -
NT - - - - -
HCA N +2 N +2 N
NT N N N N N
HCA -3 +4 -3 +4 -3
NT 5 5 5 5 5
HNF1α β-cat IHCA IHCA/β-cat UnclassifiedStains/IHC*
β-cat*
H&E1
LFABP*
SAA/CRP*
GS*
HCA: hepatocellular adenoma; IHC⁄: immunohistochemistry; NT: non tumoral liver; H&E: hematoxylin eosin (1: major ﬁndings not always observed); LFABP: liver fatty
acid binding protein (+: normal hepatocytes staining); SAA: serum amyloid A/CRP: C reactive protein (+: diffuse hepatocytes staining); b-cat: b-catenin (N: normal
membranous staining; 2: aberrant cytoplasmic/nuclear staining can be diffuse, focal or limited to few hepatocytes); GS: glutamine synthase (3: GS staining is usually
absent, occasionally some hepatocytes can be stained at the periphery of the nodule as well as around veins; 4: GS staining is usually strong and diffuse; when the staining
is heterogeneous (intensity and location) the interpretation is difﬁcult; in this case b-catenin mutation should rely on b-catenin staining or molecular analysis; 5: normal GS
staining limited to few centrolobular hepatocytes).
Information concerning outcome 
Will determine surveillance program
Present 
Results awaited  
 erutuF
Destruction (or strict surveillance) of β-catenin HCA/β-catenin IHCA 
Genetic counselling (germline HNF1A mutation) in familial adenomatosis 
and/or diabetes associated to LFABP negative HCA
Drug targeting  
Fig. 1. Reasons for the identiﬁcation of HCA subtypes (<5 cm).
JOURNAL OF HEPATOLOGYprior to surgery. The radiological diagnosis of HCA on MRI is pos-
sible in H-HCA and IHCA at least in typical cases [14]. However,
more data are necessary in order to estimate the true diagnostic
accuracy. One of the major limitations that remains is in the iden-
tiﬁcation of b-catenin mutated HCA. Indeed, it is important to
identify the b-catenin mutation because it is likely to be a marker
of premalignant HCC transformation even before traditional
pathological criteria are present (i.e. some cytological abnormal-
ities, rosette formation. . .). b-Catenin mutations occur most fre-
quently in speciﬁc conditions, such as glycogenosis, male
hormone administration (Danazol), male patient, etc. Unfortu-
nately it occurs also in the absence of etiological criteria. Unless
sampling all HCA (except H-HCA), it appears more reasonable
to follow the growth of HCA after stopping OC. HCC transforma-
tion might be unlikely if the size of the HCA decreases whereasJournal of Hepatology 2any size increase might become suspicious. In the 4 cm range
or over if surgery is not planned, it appears reasonable to recom-
mend a biopsy (allowing for HCA subtyping) and to follow the
patient in the absence of the b-catenin mutation.
The role of the biopsy has not yet been objectively evaluated.
Preliminary data from a multicentric French study [15] reveal
that the use of the same immunohistochemistry markers is
promising, particularly in the two main categories of H-HCA
and IHCA, as well as to differentiate HCA from FNH. Interpreta-
tion of immunohistochemical results may, however, even on
surgical specimen be problematic [7]. Indeed the identiﬁcation
of b-catenin mutated HCA remains the main issue, with variable
difﬁculties, particularly on biopsy, but sometimes also on surgical
specimens. The easiest situation corresponds to a strong/diffuse
GS staining associated with the presence of b-catenin labeled011 vol. 55 j 8–10 9
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nuclei (a few or numerous) that is constantly associated with an
activating b-catenin mutation. However, strong GS staining with-
out nuclear b-catenin or heterogeneous distribution of GS in the
absence of b-catenin labeled nuclei remains difﬁcult to interpret
[7]. This was conﬁrmed by Van Aalten and colleagues. In our
experience, GS and b-catenin immunohistochemical staining is
not sensitive enough to detect all b-catenin mutations in HCA
(85% sensitivity [1]). Therefore, it is particularly important that
pathologists collect frozen material for each surgical specimen
of these tumors to search for b-catenin mutations or small dele-
tions in LFABP positive and IHCA.
In addition to the identiﬁcation of b-catenin mutations, the
importance of HCA subtyping can be seen in several ways. First,
we know that speciﬁc genetic factors are associated with the
development of HCA [16–18]. Second, for patients with LFABP
negative HCA and familial adenomatosis or maturity diabetes of
the young (MODY), we propose a genetic counseling and a germ-
line HNF1A mutation screening.
Other questions remain to be elucidated: is the risk of bleed-
ing, the evolution of nodules (growth, regression) after stopping
OC (whether unique, or remaining after resection of the largest
one) subtype dependent? Is the distribution of subtypes different
according to gender, age (infants, adolescents, menopausal
women), in women never exposed to OC, and in patients subject
to vascular disorders? Is the risk of bleeding subtype dependent
in women who want to become pregnant?
The most appealing usefulness of HCA subtyping will be to
provide us with better tools to deﬁne patient treatment/surveil-
lance guidelines once HCA are discovered. Since the ﬁrst paper
showing the relationship between OC and HCA was published
in 1972, the overall picture of HCA has dramatically changed.
Indeed today, estrogen concentrations have decreased, OC are
often prescribed at a younger age, women seldom observe to
refrain from smoking and obesity is becoming a major health
problem. In the meantime smaller nodules are discovered more
frequently, and the discovery of HCA in post-menopausal women
is no longer an exception.
HCA remain rare tumors even in countries where OC are
widely prescribed. Therefore, we make a pledge that in countries
where HCA are observed, particularly in Europe, radiologists, sur-
geons, pathologists, and hepatologists from referral centers
should combine their expertise with the expertise of molecular
biologists in collaborative research programs to improve our
understanding of the disease and to better adapt treatments. It
is also important to mention that as patients are eager to access
relevant information on the web, we must provide them with
comprehensive, consensual, and validated data and in this line
van Aalten and collaborators here provide the ﬁrst international
validation of the HCA pathomolecular classiﬁcation.Conﬂict of interest
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